Chad M Barnett
Overview
Explore the profile of Chad M Barnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez A, Jones T, Ryan J, Barnett C, Soussou E, Donahue S
J Adv Pract Oncol
. 2022 Oct;
13(7):705-712.
PMID: 36199494
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that has demonstrated strong efficacy with manageable side effects for patients with germline breast cancer susceptibility genes 1 or 2 (g)- mutated, human...
2.
Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez R, Willey J, et al.
JAMA Oncol
. 2018 Jun;
4(9):1207-1213.
PMID: 29879283
Importance: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR)...
3.
DiPippo A, Patel N, Barnett C
Pharmacotherapy
. 2016 Apr;
36(6):652-67.
PMID: 27087139
Treatment of metastatic breast cancer (MBC) that is resistant to endocrine therapy presents a significant clinical challenge. The well-known role of cell cycle dysregulation in these patients is partly mediated...
4.
Murthy R, Theriault R, Barnett C, Hodge S, Ramirez M, Milbourne A, et al.
Breast Cancer Res
. 2014 Dec;
16(6):500.
PMID: 25547133
Introduction: The incidence of breast cancer diagnosed during pregnancy is expected to increase as more women delay childbearing in the United States. Treatment of cancer in pregnant women requires prudent...
5.
Baron J, Boster B, Barnett C
J Oncol Pharm Pract
. 2014 Apr;
21(2):132-42.
PMID: 24682654
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer is an aggressive form of breast cancer associated with poorer prognosis and shortened survival. Primary and acquired resistance to existing HER2-targeted therapies...
6.
Thompson L, Eckmann K, Boster B, Hess K, Michaud L, Esteva F, et al.
Oncologist
. 2014 Feb;
19(3):228-34.
PMID: 24536030
Background: Trastuzumab has become a mainstay of therapy for human epidermal growth factor receptor-2 overexpressed breast cancer in nearly all stages of the disease. Like many monoclonal antibodies, trastuzumab is...
7.
Malenfant S, Eckmann K, Barnett C
Pharmacotherapy
. 2013 Aug;
34(1):60-71.
PMID: 23918291
Trastuzumab, a humanized monoclonal antibody, has become an important targeted therapy for patients with all stages of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. However, primary and acquired resistance...
8.
Barnett C
Pharmacotherapy
. 2012 Mar;
32(4):383-96.
PMID: 22461124
The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol 3-kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth and metabolism. Dysregulation of...
9.
Watkins J, Landgraf A, Barnett C, Michaud L
J Am Pharm Assoc (2003)
. 2012 Feb;
52(2):170-4.
PMID: 22370379
Objectives: To determine the effect of formal medication therapy management (MTM) services on pharmacist workload, as well as to describe the population receiving MTM, describe the services provided, and determine...
10.
Barnett C
Pharmacotherapy
. 2009 Dec;
29(12):1482-90.
PMID: 19947807
Metastatic breast cancer is considered incurable. Despite effective response rates achieved with anthracycline or taxane anticancer drugs, cancers in approximately one third of patients fail to respond to first-line treatment...